STUDY SEARCH RESULTS

1 study found for your search request:  6482-024

A Study of Belzutifan (MK-6482) in Combination with Palbociclib Versus Belzutifan Monotherapy in Par...
Condition: Renal Cell Carcinoma
Minimum Age: 18 years, Maximum Age: N/A
Gender: All
Study ID: NCT05468697
Status: Recruiting
Has Enrolling Locations in US or Canada




Copyright © 2024 · Merck & Co., Inc., Rahway, NJ, USA, and its affiliates. All rights reserved. · This site is intended only for residents of the United States.
Cookie Preferences  Privacy  Terms of Use  U.S. Corporate Site